Multisystem Inflammatory Syndrome In Children

The American Heart Association has published a scientific statement on the association between COVID-19 infection and CV complications among children and young adults.

Older children and those with ferritin levels greater than 500 µg/L are at highest risk for severe multisystem inflammatory syndrome in children resulting in ICU admission after COVID-19, according to data published in CMAJ.

PHOENIX — Although the CDC has presented a case definition of multisystem inflammatory syndrome in children, the COVID-19 complication continues to demand attention from researchers and providers alike.

Most pediatric patients with multisystem inflammatory syndrome also had evidence of myocardial injury, but functional recovery was quick with no adverse coronary outcomes, researchers reported.

Amid the continuing COVID-19 pandemic, pediatric researchers have been continuing their examinations into the persisting multisystem inflammatory syndrome in children.

Home testing for COVID-19 is a crucial part of keeping safe this holiday season, according to William Schaffner, MD, and Amesh A. Adalja, MD. A review of proper COVID-19 precautions was the top story in infectious disease last week.

Patients with multisystem inflammatory syndrome in children experienced more severe illness during a second wave of cases compared with the first, according to a study published in The Pediatric Infectious Disease Journal.

In a randomized, double-blind, controlled study, Tavneos showed a significantly greater increase in glomerular filtration rate compared with prednisone in patients with renal disease associated with anti-neutrophil cytoplasmic antibody vasculitis.

Multisystem inflammatory syndrome in children demonstrates clinical and proteomic heterogeneity, with signals suggestive of thrombotic microangiopathy and macrophage activation syndrome, according to data presented at ACR Convergence 2021.

Researchers found that plasma osteopontin levels were higher in children hospitalized with moderate to severe COVID-19 and MIS-C, suggesting this could be a “reliable biomarker” for disease severity.